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Abstract
Purpose/Objectives
Treatment of the primary tumor reportedly improves survival in several types of metastatic
cancer. We herein evaluated the efficacy and toxicity of radiotherapy for the primary tumor
in prostate cancer with metastasis.
Materials/Methods
The study cohort included 140 men with metastatic prostate cancer at initial diagnosis. Met-
astatic sites were divided into 4 groups as follows: solitary bone, 2–4 bones,5 bones, and
visceral organs. Patient, tumor, and treatment characteristics, and clinical outcomes were
compared between patients treated with (prostate radiotherapy [PRT] group) or without
radiotherapy to the primary tumor.
Results
Patients in PRT group presented with a statistically significantly younger age (p = .02),
whereas other characteristics showed no significant difference. Overall survival (OS) and
biochemical failure-free survival (BCFFS) were improved in PRT patients (3-year OS: 69%
vs. 43%, p = 0.004; 3-year BCFFS: 52% vs. 16%, p = 0.002). Multivariate analysis identified
PRT as a significant predictor of both OS (hazard ratio [HR] = 0.43, p = 0.015). None of the
38 PRT patients experienced severe (grade3) genitourinary or gastrointestinal toxicity.
Conclusions
Our data suggest that radiotherapy to the primary tumor was associated with improved OS
and BCFFS in metastatic prostate cancer. The results of this study warrant prospective con-
trolled clinical trials of this approach in stage IV prostate cancer patients with limited extent
of bone metastasis and good performance status.
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Introduction
Aggressive treatment of the primary tumor is usually not recommended for patients with stage
IV metastatic cancers. However, in certain types of malignancy, local treatment of the primary
site with systemic therapy reportedly improves overall survival (OS) or enhances the efficacy of
other therapeutics for the metastatic disease. In 1989, the Southwest Oncology Group initiated
a randomized trial of nephrectomy in metastatic renal-cell cancer [1,2]. This study demon-
strated that nephrectomy followed by interferon therapy resulted in longer survival among
patients with metastatic renal-cell cancer than interferon therapy alone. In another trial,
nephrectomy significantly improved the median OS from 7 to 17 months [3]. In 2004, Temple
et al. reported that metastatic colon cancer patients undergoing primary tumor resection had a
better response to chemotherapy [4]. Recent retrospective studies have shown that radiother-
apy (RT) to or surgical excision of the primary tumor is associated with a better prognosis in
patients with metastatic breast cancer [5,6]. Furthermore, the prognosis of stage IV metastatic
diseases is relatively good in the above-mentioned cancer types. Even in advanced cancer, local
treatment becomes more important as patient survival time increases because it can prevent
subsequent distant seeding and relieve local symptoms due to progression of the primary site.
Similarly, prostate cancer patients with stage IV metastatic diseases also have a relatively
good survival [7]. Hormonal therapy is the most commonly used first-line therapy for meta-
static prostate cancer [8]. However, systemic therapy alone has resulted in a median survival of
no more than 36 months in metastatic prostate cancer patients [9–11]. An intuitive argument
is that in potentially metastatic cancer, the longer the primary tumor remains, the more meta-
static events will occur [12]. Cytoreductive treatment via primary tumor radiotherapy may
have a role in the management of metastatic prostate cancer.
Moreover, the systemic effect of RT, called the abscopal effect, has been explored in several
studies [13,14]. The local inflammatory reactions generated by RT activate several immunolog-
ical signals and contribute to better antigen cross-presentation leading to CD8+cytotoxic T-cell
activation. In other words, the signals induced by RT could convert the irradiated tumor into
an immunogenic antigen and the host’s immune system response to the tumor can contribute
both to the local response to RT and to a systemic rejection of metastasis [14].
In general, local treatment for the primary tumor includes surgery and radiotherapy. For
prostate cancer, radiation therapy is less invasive with newly developed techniques to minimize
side effects [15]. If the therapy is well tolerated with minimal side effects, more aggressive treat-
ment to the primary tumor can be applied in metastatic diseases.
In the present study, we aimed to investigate the role of radiotherapy to the primary tumor
in patients with prostate cancer presenting as M1 diseases, with an assumption that the natural
course of the diseases could be improved if the primary tumors are treated locally together with
systemic therapy.
Materials and Methods
Patient eligibility
We identified 3,578 consecutive men who were diagnosed with prostate cancer between 2003
and 2011 at our institution. All men presented with metastatic disease at initial diagnosis or
within 1 month from the initial diagnosis were included. Patients with other primary malig-
nancies or those who underwent prostatectomy before radiotherapy were excluded. The final
study cohort of this study included 140 men. The American Joint Committee on Cancer
(AJCC) stage was used to classify metastatic disease. Metastases to the pelvic lymph node (LN),
including the obturator, iliac, sacral, and hypogastric LN were defined to be regional LN
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metastases, and metastases beyond the pelvic cavity were classified as distant metastases, clini-
cally M1 disease.
This study was approved by Institutional review board (IRB) of Yonsei University Health
System (IRB protocol number 4-2014-0842). All data were collected by analyzing medical
reports and information in our institutional medical records. However, due to the retrospective
aspect of this study, patient informed consent was not provided for this study. But all subjects
had provided written permission for their medical records to be used for research purposes as
provided for.
Treatment type and indication
Of 140 eligible men in this study, 63 (45%) did not receive any radiotherapy. Among 77
patients (55%) who received radiotherapy, local radiotherapy to the primary tumor was
performed in 38 patients (27%) (Fig 1A). In the present study, local treatment to the pri-
mary tumor was confined to radiotherapy delivered to the prostate, but not surgery. Radio-
therapy was delivered to the prostate with pre-defined margins according to European
Organisation for Research and Treatment of Cancer (EORTC) guideline [16], and meta-
static lesions were treated to include gross tumor volume and appropriate margins (Fig 1B).
Indication for radiotherapy to the prostate was decided based on the needs of patients with
urinary symptoms and personalized at the discretion of the treating radiation oncologist.
Systemic therapy, as indicated by the treating urologist or oncologist, might be given before
radiotherapy and immediately after diagnosis. Indications for radiotherapy to metastatic
lesions included pain, risk of fracture, and neurologic complications or disease control
without any symptom. Most patients (96%) started androgen deprivation therapy at the
time of initial diagnosis.
Fig 1. Treatment scheme of all patients (A) and an example of the treatment for a patient receiving prostate radiotherapy (B).
doi:10.1371/journal.pone.0147191.g001
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Outcome and toxicity analysis
In this study, the primary endpoint was OS, and the secondary endpoints included biochemical
failure-free survival (BCFFS). The Phoenix definition (nadir + 2 ng/mL) is commonly used due
to several limitations of the previous ASTRO definition. However, the Phoenix definition also
has limitations and a controversy still exists. We defined BCFFS as three consecutive increases
in the prostate-specific antigen (PSA) level after nadir (ASTRO definition) for the following
reasons. First, our patients had metastatic disease with more extensive lesions and their base-
line PSA level was relatively higher (median 190 ng/mL, range 3.1–17800 ng/mL) than those
without metastasis. Second, unless all tumors are cured, there are still residual tumors and the
nadir PSA levels do not fall to subclinical levels (<4 ng/ml) in many patients. Third, patients
treated with ADT frequently show PSA bounces [17] and a nadir + 2 ng/mL definition could
result in more false-positive incidents in metastatic patients. In addition, the definition of cas-
tration-resistant prostate cancer is rising PSA levels or progressive disease in the setting of
serum testosterone levels within the castrate range (< 50 ng/dl) [18]. Overall, considering these
reasons, we thought the ASTRO definition is more applicable in metastatic cancer and we used
the ASTRO definition in our study.
Toxicity monitoring was performed on patients receiving radiotherapy during all follow-up
visits. Gastrointestinal (GI) or genitourinary (GU) toxicity was scored according to the Radia-
tion Therapy Oncology Group and EORTC criteria. Hematologic toxicity was scored according
to the Common Terminology Criteria for Adverse Events version 4.0. Each patient who
received radiotherapy underwent weekly hematologic evaluation. The parameters included all
hematologic abnormalities, GI or GU symptoms, and other adverse events reported by
patients.
Statistical analysis
Two groups of patients were analyzed in this study: those whose primary tumor was treated
with radiotherapy (the prostate radiotherapy [PRT] group) and those who did not received
radiotherapy to their primary tumor. Comparisons of patient and treatment characteristics
between the two groups were performed using the chi-square and Fisher exact tests. The rates
of OS and BCFFS were calculated by the Kaplan–Meier method. Statistical significance of sur-
vival differences was examined using the log-rank test. Cox’s regression model was used for
multivariate analysis of OS. All significance was established at p< 0.05. All statistical analyses
were performed using the SPSS software package, version 20.0.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient and radiotherapy characteristics
Table 1 summarizes the clinical characteristics of the entire cohort and comparison between
patients who received prostate radiotherapy and those who did not. The median age was 69
years, and 55% of the patients were70 years. The Eastern Cooperative Oncology Group
(ECOG) performance status was 0–1 in 79% of patients; 74% had a Gleason score8; and the
initial PSA levels were100 ng/mL in 61% of patients. The number of metastatic lesions on
initial presentation was 1 in 13% of patients, 2–4 in 30%, and5 in 40%, with 78% of the cases
being bone metastases. Age was the only factor with significant distribution difference between
PRT and non-PRT patients, whereas no significant differences in the distribution of perfor-
mance status, Gleason score at diagnosis, initial PSA level, disease extent, metastatic site, and
the use and duration of androgen deprivation therapy were observed between the two groups.
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All patients received conventional or hypo-fractionated radiotherapy with a median dose of
60 Gy in 24 fractions (fx) (varying from 30 Gy/10 fx-72.6 Gy/33 fx) to the prostate (1.8–4 Gy
per fraction). Common radiation schedules were 70 Gy/28fx (BED3 = 128.3 Gy) in 11 patients
(29%) and 55 Gy/20fx (BED3 = 105.4 Gy) in 10 patients (26%). No patients received stereotac-
tic body radiotherapy. Metastatic lesions received a median dose of 40 Gy in 10 fractions
(range 22.5–54 Gy). Fifty-five (71%) patients were treated with tomotherapy, while others
received conventional 3D-conformal radiotherapy. The extent and site of radiotherapy in the
PRT and palliative radiotherapy groups are described in Fig 2.
The median nadir PSA level was relatively lower in the PRT group (1.12 vs. 0.61 ng/mL,
p = 0.042) and more patients in the PRT group showed subclinical PSA levels (nadir PSA<4
ng/mL) than those in the non-PRT group (87% vs.55%, p = 0.002) (Table 1).
Survival
The median follow-up time was 34.0 months (range, 1.7–108.8 months) in the entire cohort.
The 3-year OS of all patients was 48.2%, and BCFFS was 25%. The 3-year OS rate was higher in
men receiving PRT than in those who did not (3-year OS: 69% vs. 43%, p = 0.004). Significantly
Table 1. Characteristics of the entire patient cohort and comparisons between patients with and without prostate radiotherapy (PRT).
Entire cohort PRT (−) PRT (+) p value
N = 140 N = 102 N = 38
Characteristic N (%) N (%) N (%)
Age (years) <70 77 (55) 50 (49) 27 (71) 0.02
70 63 (45) 52 (51) 11 (29)
ECOG status 0–1 111 (79) 77 (75) 34 (89) 0.099
2–3 29 (21) 25 (25) 4 (11)
Histology Adenoca 136 (97) 98 (96) 38 (100) 0.216
Others 4 (3) 4 (4) 0 (0)
Type Acinar 120 (86) 89 (87) 31 (82) 0.427
Others 14 (10) 10 (10) 4 (11)
Unknown 6 (4) 3 (3) 3 (8)
GS 8 104 (74) 79 (77) 25 (66) 0.122
<8 22 (16) 16 (16) 6 (16)
Unknown 14 (10) 7 (7) 7 (18)
Hormonal therapy Yes 136 (97) 98 (96) 38 (100) 0.213
No 4 (3) 4 (4) 0 (0)
iPSA (ng/mL) Median 191.5 221.0 126.0 0.134
<100 54 (39) 36 (35) 18 (47) 0.426
100–200 17 (12) 13 (13) 4 (11)
>200 69 (49) 53 (52) 16 (42)
Number of metastases 1 25 (13) 13 (13) 12 (32) 0.642
on presentation 2–4 42 (30) 30 (29) 12 (32)
5 57 (40) 46 (45) 11 (29)
Metastasis Visceral + others 32 (23) 27 (26) 5 (15) 0.126
Bone only 108 (77) 75 (74) 33 (85)
Nadir PSA (ng/mL) Median 1.11 1.12 0.61 0.042
Nadir PSA < 4 ng/mL 89 (64) 56 (55) 33 (87) 0.02
Abbreviations: PRT, prostate radiotherapy; ECOG, Eastern Cooperative Oncology Group; GS, Gleason score; iPSA, initial prostate-speciﬁc antigen.
doi:10.1371/journal.pone.0147191.t001
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prolonged BCFFS was also observed in the PRT group (3-year BCFFS: 52% vs. 16%, p = 0.002)
(Fig 3A). Subgroup analysis was performed for the non-PRT patients. Of these, 39 patients
received palliative radiotherapy to the metastatic sites with androgen deprivation treatment,
whereas the others (n = 63) received systemic therapy only. No significant differences in OS
(3-year: 50% vs. 40%, p = 0.441) and BCFFS (3-year 10% vs. 20%, p = 0.293) were observed
between patients receiving palliative radiotherapy and those who did not (Fig 3B).
Prognostic factors
Univariate analysis revealed that ECOG performance status, metastatic site, disease extent, and
PRT were significant factors for OS. Furthermore, multivariate analysis confirmed irradiation
to the prostate as a significant predictor of both OS (hazard ratio [HR] = 0.5, p = 0.046)
(Table 2). For BCFFS, site of metastasis (bone vs. non-bone) and ECOG performance status
scores (0–1 vs. 2–3), Gleason score and extent of disease did not show any significance (all
p> 0.05), except PRT (p< 0.001) in univariate analysis.
Toxicities in PRT group
None of the 38 patients in the PRT group experienced severe (grade3) GU or GI toxicity. In
this group, 4 patients (11%) had grade 3 thrombocytopenia, and 3 (8%) had grade 3
Fig 2. Extent and site of radiotherapy for patients receiving prostate radiotherapy (PRT) or palliative radiotherapy (RT). Non spine*: site of bone
metastasis except in the pelvic bone and spine (C-T-L spine).Pelvis**: bone metastasis, including metastasis to the pubic, ischial, and iliac bones and the
sacrum and proximal femur.
doi:10.1371/journal.pone.0147191.g002
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leukocytopenia. Several patients received transfusion to prevent more severe adverse events,
and most of the side effects were tolerable.
Discussion
Our results from this study indicated that radiotherapy for the primary tumor improved prog-
nosis of patients with metastatic prostate cancer. Men who received radiotherapy to the pri-
mary tumor had a favorable OS compared to those who did not (3-year OS: 69% vs. 43%,
Fig 3. (A) Kaplan–Meier curves for overall survival (OS) and biochemical failure-free survival (BCFFS) of patients receiving prostate radiotherapy
(PRT) and those who did not. OS (p = 0.004) and BCFFS (p = 0.002) were better in PRT patients than in non-PRT patients. (B) Kaplan-Meier curves
for overall survival (OS) and biochemical failure-free survival (BCFFS) of non-prostate radiotherapy (PRT) patients with and without palliative
radiotherapy (RT). In the non-PRT group, OS and BCFFS did not differ significantly between patients receiving palliative RT and those receiving non-
palliative RT.
doi:10.1371/journal.pone.0147191.g003
RT for Primary Prostate Cancer of Patients with Distant Metastasis
PLOS ONE | DOI:10.1371/journal.pone.0147191 January 25, 2016 7 / 12
p = 0.004). Such improvement of prognosis was observed not only in OS but also in BCFFS
(3-year BCFFS: 52% vs. 16%, p = 0.002). The effect of treatment was not significantly different
among patients with various extent of metastasis. However, results of a stratified analysis sug-
gested a greater effect among patients with only bone metastases at diagnosis and with good
performance status.
Currently, radiotherapy for prostate cancer patients with distant metastasis is limited to pal-
liative treatment to relieve local symptoms such as pain or urinary problems. Treatment of the
primary tumor is often regarded inappropriate if metastasis is present. Moreover, Camphausen
et al. revealed that the use of radiation to primary tumor resulted in the progression of previ-
ously dormant lung metastases by an imbalance of proangiogenic over antiangiogenic fartors
in mice model [19]. However, in our study, radiotherapy to the primary prostate tumor did not
impair survival but improved overall survival. This finding is consistent with previously
reported findings of other malignancies, such as renal cell cancer, colorectal cancer, and breast
cancer, for which a local treatment of primary tumor is effective in improving patients survival
[2–5].
There is biologic evidence to support our proposal to treat primary tumor in patients with
distant metastasis. Extensive experimental models had confirmed Paget’s original ‘‘seed and
soil” theory that hypothesize the organ-preference of metastasis formation is the result of inter-
actions between circulating tumor cells (the ‘‘seed”) and organ microenvironment (the ‘‘soil”)
[20]. Not only supplying the “seed,” the primary tumor also has a major role to prepare the
“soil”. Kaplan et al. reported that the initial event at a metastatic site is not the arrival of circu-
lating tumor cells, but the recruitment of bone marrow-derived cells (BMDCs) at the metastatic
site. These BMDCs make the microenvironment of the metastatic organ more acceptable to
colonization of tumor cells forming ‘pre-metastatic niche’ [21]. Such a finding implicates that
therapy directed toward the primary tumor, by inhibiting the endocrine molecules secreted by
primary tumor, could delay the formation and growth of distant metastases. Weckermann
et al. also evaluated the disseminated tumor cells (DTCs) before and after prostatectomy by
analyzing the cytokeratin-positive (CK+) cells in bone marrow since CK+ cells were regarded
Table 2. Univariate andmultivariate analyses of overall survival.
Characteristics Group No Univariate analysis Multivariate analysis
3-year rate (%) p value HR p value
Age (years) <70 77 53 0.075
70 63 39
ECOG status 0–1 111 65 0.004 1.57 0.121
2–3 29 23
GS <8 22 41 0.758
8 104 54
Metastasis site Bone only 107 52 0.005 1.85 0.058
Others 33 3
Disease extent 1 25 57 0.007 0.096
2–4 41 41
5 66 28
Visceral 8 0
PRT (+) 35 43 0.012 0.43 0.015
(–) 105 62
Abbreviations: PRT, prostate radiotherapy; ECOG, Eastern Cooperative Oncology Group; GS, Gleason score.
doi:10.1371/journal.pone.0147191.t002
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as indicators of disseminated tumor cells (DTCs) [22]. They reported that DTCs before prosta-
tectomy were significantly associated with an increased risk of metastases, but DTCs after sur-
gery were not. This result suggested that the increased risk of metastasis manifested by DTCs
was associated with an intact primary tumor and is consistent with the hypothesis that factors
from the primary tumor are required to stimulate DTCs to colonize and grow.
A recent large-scale retrospective analysis also reports interesting findings. Positive pelvic
lymph node is deemed to be a risk factor for distant metastasis and local therapy is in general
omitted in favor of androgen-deprivation therapy. A study of the Munich Cancer Registry ana-
lyzed treatment outcomes in 938 prostate cancer patients with nodal metastases at the time of
pelvic lymph node dissection [23]. Patients who underwent radical prostatectomy showed
much favorable outcome compared to those who did not (10-year OS 64% vs. 28%). Although
the group with radical prostatectomy had more favorable features, these findings showed at
least a possible benefit from aggressive local treatment in patients with metastatic disease.
A possible hypothesis for treatment of the primary tumor could be the abscopal effect. How-
ever, this is less likely to happen after conventional fractionated RT alone, which may be insuf-
ficient to generate a systemic and robust antitumor effect. As initial treatment for metastatic
prostate cancer or castration-resistant prostate cancer (CRPC), other systemic treatments as
well as ADT could be administered. Docetaxel-based systemic chemotherapy has been gener-
ally used to treat metastatic prostate cancer after the approval of docetaxel in 2004 [24]. In
addition, sipuleucel-T, an autologous prostatic acid phosphatase (PAP) directed cell-based
immunotherapy product manufactured using patients’ own antigen-presenting cells, showed a
survival benefit in a randomized phase III trial, and is recommended with category 1 evidence
for patients who have a life expectancy of at least 3 months with a good performance status
[25]. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) blockade via the monoclonal antibody ipili-
mumab also has attracted attention due to positive results in patients with metastatic mela-
noma and renal cell carcinoma, as well as several other malignancies [26]. Ipilimumab is also
currently being evaluated in the prechemotherapy and postchemotherapy settings in men with
metastatic CRPC. Further evidence of the efficacy of combined modalities for metastatic pros-
tate cancer is needed so that systemic control and a radiation-induced immune response can
be amplified sufficiently.
Another practical reason for us to suggest primary tumor radiotherapy for stage IV prostate
cancer is that recently developed techniques have significantly reduced treatment-related side
effects. In other words, addition of the primary tumor in the radiotherapy field does not cause
patient discomfort. In this study, 71% of patients in the PRT group received intensity-modu-
lated radiotherapy (IMRT) using helical tomotherapy and no patient experienced severe (grade
3) GI or GU toxicity. The IMRT is a newer radiotherapy technique that uses intensity-modu-
lated beams to provide multiple intensities, allowing more concave dose distribution than con-
ventional techniques. Furthermore, the chronic and acute toxicities associated with
radiotherapy for prostate cancer are well documented [27]. In the era of IMRT, several studies
have demonstrated the feasibility and efficacy of IMRT for prostate cancer in a large number of
patients. Acute and late GI and GU toxicities seem to be significantly lower than those observed
with conventional 3D-conformal radiotherapy techniques [15]. Moreover, IMRT using helical
tomotherapy makes it possible to treat a wide range of lesions including the prostate and meta-
static sites simultaneously. Compared to other local treatment such as prostatectomy. Based on
a risk versus benefit analysis, radiotherapy with this less invasive and more effective treatment
technique is suitable for prostate cancer patients with distant metastases, compared to other
local treatments such as prostatectomy.
However, IMRT using helical tomotherapy could treat a wide range of metastatic lesion
which is spreading vertical axes and most common acute side effect in PRT group was
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thrombocytopenia and leukocytopenia. Previous report in our institution suggested that the
tolerance cutoff point of red marrow was 26.8% to avoid severe leukocytopenia (grade3)
[28]. With this finding, we have taken into account for the proportion of bone marrow when
we treat wide range of bone metastasis.
In this study, good performance status, bone only metastasis and limited disease extent were
identified as prognostic factors for OS (ECOG PS 0–1 vs. 2–3, 3-yr OS 65% vs. 23%, p = 0.004;
bone only metastasis vs. others, 3-yr OS 52% vs. 3%, p = 0.005; disease extent, single metastasis
vs. 2–4 metastases vs.5 metastases 3-yr OS 57% vs. 41% vs. 28%, respectively, p = 0.007). Our
results showing a better prognosis in patients with bone-only metastasis are consistent with
observations from a recent study of patients from the SEER database. This study reported that
men with visceral metastasis showed inferior OS to that of men with bone-only metastasis
[29]. These findings suggested that prostate may have several phenotypes that predispose to
different natural histories when survival represents the end point. While the underlying mecha-
nism of different survival outcome according to the metastatic site observed between studies
unclear, we emphasize that retrospective studies should be cautiously interpreted within their
limitations.
The association with limited disease extent and survival benefit in metastatic disease has
been studied in other tumors including breast cancer, renal cell carcinoma and colorectal can-
cer [4,30,31]. Nguyen et al. revealed that limited metastatic disease, defined as<5 metastatic
lesions is a favorable prognostic factor in stage IV breast cancer (5-yr OS 29.7% vs. 13.1%,
p<0.001). They also found that locoregional treatment for breast cancer improved overall sur-
vival (5-yr OS 35.5% vs. 20.4%, p = 0.01). These results are in accordance with our study. Prog-
nostic factors defined in this study could help the clinicians identify reasonable candidates for
radiotherapy to primary tumor and evaluate appropriate treatment strategies. Selected patients
with limited extent of bone metastasis in good performance status could obtain the maximum
benefit from this treatment strategy.
As the present investigation is not a randomized study, it is important to consider the possi-
bility of selection bias due to unrecorded factors. In such a case, the differences in mortality
risk observed between patients receiving PRT and those who did not could reflect the lower uti-
lization of PRT in men with putative poorer disease prognosis. In addition, further evaluations
including metastatic markers or immunohistochemical staining results for understanding the
biologic behavior of tumors and metastatic sites are needed. Therefore the results of this pilot
study warrant a subsequent prospective randomized control trial to find out the effectiveness
of aggressive treatment to primary prostate gland in patients with stage IV prostate cancer. The
STAMPEDE (the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of
Drug Efficacy) trial fromMedical Research Council Clinical Trials Unit (MRC CTU) was initi-
ated in 2013 and result from this trial could prove the benefit of PRT [32].
Conclusions
Radiotherapy including treatment of the primary tumor for prostate cancer patients with dis-
tant metastasis resulted in improved biochemical control and long-term survival. The results of
this study warrant a randomized controlled clinical trial to confirm these.
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